SG165385A1 - Novel physiological substance nesfatin, substance relevant thereto, and use of the substances - Google Patents
Novel physiological substance nesfatin, substance relevant thereto, and use of the substancesInfo
- Publication number
- SG165385A1 SG165385A1 SG201006710-6A SG2010067106A SG165385A1 SG 165385 A1 SG165385 A1 SG 165385A1 SG 2010067106 A SG2010067106 A SG 2010067106A SG 165385 A1 SG165385 A1 SG 165385A1
- Authority
- SG
- Singapore
- Prior art keywords
- genes
- body weight
- substance
- polypeptides
- nesfatin
- Prior art date
Links
- 239000000126 substance Substances 0.000 title abstract 4
- 230000037396 body weight Effects 0.000 abstract 5
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000623 proteins and genes Proteins 0.000 abstract 5
- 238000004260 weight control Methods 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000030814 Eating disease Diseases 0.000 abstract 2
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 2
- 235000021407 appetite control Nutrition 0.000 abstract 2
- 235000014632 disordered eating Nutrition 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 abstract 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 abstract 1
- 229940123464 Thiazolidinedione Drugs 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 235000021229 appetite regulation Nutrition 0.000 abstract 1
- 150000001467 thiazolidinediones Chemical class 0.000 abstract 1
- 239000013585 weight reducing agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/02—Nutritional disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/044—Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/303—Eating disorders, e.g. anorexia, bulimia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005184441 | 2005-06-24 | ||
| JP2006064678 | 2006-03-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG165385A1 true SG165385A1 (en) | 2010-10-28 |
Family
ID=37570595
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201006711-4A SG165386A1 (en) | 2005-06-24 | 2006-06-23 | Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
| SG201006710-6A SG165385A1 (en) | 2005-06-24 | 2006-06-23 | Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG201006711-4A SG165386A1 (en) | 2005-06-24 | 2006-06-23 | Novel physiological substance nesfatin, substance relevant thereto, and use of the substances |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1900813A4 (ja) |
| JP (1) | JP5640230B2 (ja) |
| KR (1) | KR20080028888A (ja) |
| CN (1) | CN101300346B (ja) |
| AU (1) | AU2006260088B2 (ja) |
| BR (1) | BRPI0612279A2 (ja) |
| CA (1) | CA2613257A1 (ja) |
| IL (1) | IL188288A (ja) |
| NO (1) | NO20080412L (ja) |
| NZ (1) | NZ565253A (ja) |
| RU (1) | RU2418002C2 (ja) |
| SG (2) | SG165386A1 (ja) |
| TW (1) | TWI395948B (ja) |
| WO (1) | WO2006137597A1 (ja) |
| ZA (1) | ZA200711105B (ja) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1986008A1 (en) * | 2007-04-06 | 2008-10-29 | Teijin Pharma Limited | A method for screening a regulator of nesfatin-1 function or a nesfatin-1 like substance using receptor protein selected from the group consisting of GPR3, GPR6 and GPR12 |
| WO2009025401A1 (en) * | 2007-08-23 | 2009-02-26 | Teijin Pharma Limited | Nesfatin-1 specific antibody and the use thereof, and nesfatin specific antibody and the use thereof |
| JP4691571B2 (ja) * | 2008-03-04 | 2011-06-01 | 株式会社マルハニチロ食品 | 摂食調節剤 |
| US8703707B2 (en) * | 2008-07-17 | 2014-04-22 | The Rockefeller University | Nucleobindin I variant protein compositions and methods of use |
| WO2010028676A1 (en) * | 2008-09-09 | 2010-03-18 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US9018159B2 (en) | 2009-03-12 | 2015-04-28 | Landing Biotech, Inc. | Plasma anti-diabetic NUCB2 peptide (pladin) and uses thereof |
| EP2229952B1 (en) * | 2009-03-12 | 2014-08-13 | Jian-Ning Liu | Plasma anti-diabetic NUCB2 peptide (pladin and nesfatin-1n) and uses thereof |
| CN104918639B (zh) | 2012-10-22 | 2018-01-26 | 萨拜格Rfa公司 | 用于将治疗剂递送到活细胞和细胞核中的系统 |
| CN106589101A (zh) * | 2016-11-30 | 2017-04-26 | 青岛大学 | 一种nesfatin多肽及其相关物质和用途 |
| CN108949880B (zh) * | 2018-08-03 | 2021-07-20 | 吉林大学 | 一种牛脊髓肽的制备方法及其应用 |
| CN114761418A (zh) * | 2019-12-02 | 2022-07-15 | 株式会社Lg化学 | Cho细胞衍生的蛋白分泌因子和包含它的表达载体 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
| US4873191A (en) | 1981-06-12 | 1989-10-10 | Ohio University | Genetic transformation of zygotes |
| EP0127839B1 (en) | 1983-05-27 | 1992-07-15 | THE TEXAS A&M UNIVERSITY SYSTEM | Method for producing a recombinant baculovirus expression vector |
| CA1332049C (en) | 1988-10-07 | 1994-09-20 | Eli Lilly And Company | Eukaryotic expression |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6753314B1 (en) * | 1999-04-01 | 2004-06-22 | Curagen Corporation | Protein-protein complexes and methods of using same |
| JP2002017186A (ja) | 2000-06-30 | 2002-01-22 | Hayashibara Biochem Lab Inc | トランスジェニック植物 |
| JP2003116385A (ja) | 2001-10-15 | 2003-04-22 | Univ Of The Ryukyus | 日本脳炎ワクチンをコードする遺伝子を含むトランスジェニック植物 |
| JP2003342201A (ja) | 2002-03-20 | 2003-12-03 | Cardio Corp | 遺伝子細胞治療剤 |
| JP3887658B2 (ja) | 2002-03-27 | 2007-02-28 | 新潟県 | 遺伝子導入用の植物細胞処理装置 |
-
2006
- 2006-06-23 BR BRPI0612279-5A patent/BRPI0612279A2/pt not_active IP Right Cessation
- 2006-06-23 SG SG201006711-4A patent/SG165386A1/en unknown
- 2006-06-23 TW TW095122760A patent/TWI395948B/zh not_active IP Right Cessation
- 2006-06-23 WO PCT/JP2006/313041 patent/WO2006137597A1/ja active Application Filing
- 2006-06-23 EP EP06780673A patent/EP1900813A4/en not_active Withdrawn
- 2006-06-23 CA CA002613257A patent/CA2613257A1/en not_active Abandoned
- 2006-06-23 JP JP2007522404A patent/JP5640230B2/ja active Active
- 2006-06-23 AU AU2006260088A patent/AU2006260088B2/en not_active Ceased
- 2006-06-23 KR KR1020077030221A patent/KR20080028888A/ko not_active Application Discontinuation
- 2006-06-23 CN CN2006800226228A patent/CN101300346B/zh not_active Expired - Fee Related
- 2006-06-23 SG SG201006710-6A patent/SG165385A1/en unknown
- 2006-06-23 RU RU2008102731/10A patent/RU2418002C2/ru not_active IP Right Cessation
- 2006-06-23 NZ NZ565253A patent/NZ565253A/en not_active IP Right Cessation
-
2007
- 2007-12-20 ZA ZA200711105A patent/ZA200711105B/xx unknown
- 2007-12-20 IL IL188288A patent/IL188288A/en not_active IP Right Cessation
-
2008
- 2008-01-22 NO NO20080412A patent/NO20080412L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20080028888A (ko) | 2008-04-02 |
| JP5640230B2 (ja) | 2014-12-17 |
| CA2613257A1 (en) | 2006-12-28 |
| SG165386A1 (en) | 2010-10-28 |
| AU2006260088A1 (en) | 2006-12-28 |
| TW200741205A (en) | 2007-11-01 |
| RU2418002C2 (ru) | 2011-05-10 |
| WO2006137597A1 (ja) | 2006-12-28 |
| RU2008102731A (ru) | 2009-07-27 |
| AU2006260088B2 (en) | 2012-07-12 |
| CN101300346A (zh) | 2008-11-05 |
| NZ565253A (en) | 2011-06-30 |
| JPWO2006137597A1 (ja) | 2009-01-22 |
| EP1900813A4 (en) | 2009-08-05 |
| CN101300346B (zh) | 2013-04-24 |
| ZA200711105B (en) | 2009-08-26 |
| TWI395948B (zh) | 2013-05-11 |
| NO20080412L (no) | 2008-03-18 |
| BRPI0612279A2 (pt) | 2009-01-27 |
| WO2006137597A9 (ja) | 2008-05-29 |
| IL188288A0 (en) | 2008-04-13 |
| IL188288A (en) | 2013-08-29 |
| EP1900813A1 (en) | 2008-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG165386A1 (en) | Novel physiological substance nesfatin, substance relevant thereto, and use of the substances | |
| IL225203A (en) | An isolated complementary factor polypeptide, methods for its preparation, its uses and a factor that lowers its expression or activity | |
| MX2010004450A (es) | Derivados heterociclo biciclicos y su uso como moduladores de la actividad de gpr119. | |
| WO2005113590A3 (en) | Bmp10 propeptides and related methods | |
| MY151018A (en) | Use of nutritional compositions for preventing disorders | |
| WO2006034455A3 (en) | Polipeptide compounds for inhibiting angiogenesis and tumor growth | |
| WO2007143098A3 (en) | Hepatocyte growth factor (hgf) binding proteins | |
| WO2008036678A3 (en) | Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis | |
| EP1863562A4 (en) | METHOD FOR TREATING DEPRESSION, ATMOSPHERIC STATES AND FEASIBILITY WITH NEUROMODULATION | |
| WO2006015060A3 (en) | Isoindoline compounds and methods of their use | |
| GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
| GB2478065A (en) | Method and systems for personalized action plans | |
| EP2286840A3 (en) | Treatment of obesity and related diseases | |
| JP2007517055A5 (ja) | ||
| EP1740178A4 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT, PREVENTION OR MANAGEMENT OF SLEEP DISORDERS AND SLEEP DISORDERS ASSOCIATED WITH A DISEASE | |
| WO2008039566A3 (en) | Drugs and uses | |
| WO2006064375A2 (en) | Aminoaryl substituted five-membered ring heterocyclic compounds for the treatment of diseases | |
| ZA200606834B (en) | 1-Aminocyclohexane derivatives for the treatment of agitation and other behavioral disorders, especially those associated with Alzheimer's disease | |
| WO2005115446A3 (en) | Detection and use of prolylcarboxypeptidase | |
| EP2674165A3 (en) | Hepatocyte growth factor receptor agonist for increasing lymphangiogenesis | |
| WO2005115548A3 (en) | Treating depressive disorders with carbonic anhydrase activators | |
| WO2006048877A3 (en) | Treatment of b-cell malignancies with fgfr3 inhibitors | |
| WO2008147483A3 (en) | Neurogenic compounds | |
| ATE449769T1 (de) | 3-(4-ää4-(4ää3-(3,3-dimethyl-1- piperidinyl)propyläoxyüphinylü-1- piperidinylcarbonylü-1-naphthalinyl)propan- oder propensäure als h1- und h3-rezeptor-antagonisten zur behandlung entzündlicher und/oder allergischer erkrankungen | |
| ZA200300210B (en) | Use of oxygen analysis by GC-AED for control of Fischer-Tropsch process and product blending. |